All News
Cost of Osteoporosis Care in the USA
The 2010 NHANES study suggests that the overall prevalence of osteoporosis (OP) in the USA is ~10% or 10.2 million older adults (> 50 yrs) had osteoporosis.
Read Article
Another Biosimilar Approval - Etanercep-szzs by Novartis
Yesterday the U.S. Food and Drug Administration approved a new biosimilar, Erelzi, (etanercept-szzs), for the same multipile indications as the originator Enbrel, including rheumatoid arthritis, plaque psoriasis, Erelzi, will be generically labelled as etanercept-szzs.
Read Article
RheumNow Week in Review – 26 August 2016
Dr. Jack Cush reviews news and journal reports from the past week on RheumNow.com.
Read Article
Prior Cancer Patients May Safely Receive TNF Inhibitors or Rituximab
Current guidelines regarding the use of biologics in patients who have previously had a malignancy are based more on opinion than evidence.
Read Article
Adalimumab Controls Non-Infectious Uveitis in VISUAL II Study
It has long been observed that patients receiving monoclonal antibody based anti-TNF (TNFi) therapies for spondylitis or psoriatic disease have less inflammatory eye complications, such as uveitis. These agents have become common interventions based on these observational results.
Read Article
Risk of Sepsis or Death Lower with Biologics in Rheumatoid Arthritis
Researchers from Germany have analyzed their large prospective rheumatoid arthritis (RA) registry to address whether being on biologic therapies leads to poorer outcomes - namely sepsis or death, following a serious infection (SIE).
Read Article
RheumNow Week in Review – 19 August 2016
Dr. Cush reviews the RheumNow.com highlights in rheumatology for the week ending 19 August 2016.
Read Article
ARCTIC Study Shows No Benefit to Ultrasound Remission in RA
The goal in rheumatoid arthritis (RA) treatment is remission. But what level or method of remission is best?
Read Article
Remicade Patent Infringements Denied: Opens Door for New Biosimilars
A U.S. court has affirmed its decision that the patent for Johnson & Johnson's drug Remicade is invalid. This new ruling favors the intent of Celltrion and Pfizer, who are seeking to bring their biosimilar versions of infliximab to market in the near future.
Read Article
Fewer Psoriasis Patients Satisfied with Current Treatments
A new national survey in the United States of nearly 600 individuals with psoriasis, reveals that although patients have numerous treatment options, they have difficulty finding treatment plans that work. In addition, respondents reported a heavy emotional toll, with many feeling isolated and stigmatized due to the condition.
Read Article
RheumNow Week in Review – 12 August 2016
Watch Dr. Cush review 13 highlights from this week on RheumNow.
Read Article
No Added Lymphoma Risk with TNF Inhibitor Use
Warnings of cancer, especially lymphoma, have accompanied the development and promotion of tumor necrosis factor inhbitors (TNFi) in the treatment of RA and other inflammatory disorders.
Read Article
Etanercept May Lower Alzheimers Risk in Rheumatoid Arthritis
The pathogenesis of Alzheimer's disease (AD) is unknown but some have speculated a role for inflammation.
Read Article
Severe, Refractory Psoriasis in HIV-Positive Patients: Are TNF Inhibitors a Solution?
Psoriasis and psoriatic arthritis are more prevalent, often more severe, and sometimes refractory to conventional treatments in HIV-positive patients, but clinicians are understandably concerned about moving on to immunosuppressive anti-tumor necrosis factor (TNF) agents when other treatments fai
Read Article
Biosimilars are Bioequivalent to Original TNF Inhibitors
Chingcuanco and coinvestigators have reported on their comparative analysis of biosimilars and their originator TNF inhibitors in the current issue of Annals of Internal Medicine. (Citation source: http://buff.ly/2arTd1q)
Read Article
RheumNow Week in Review - 29 July 2016
Dr Jack Cush reviews this week's highlights from RheumNow.com.
Read Article
Long-Term Safety of Adalimumab Reviewed
Burmester and colleagues have published their review of the long-term outcomes and safety issues with the TNF inhibitor, adalimumab (ADA). The analysis included 15,132 patients exposed to adalimumab in global RA clinical trials.
Read Article
Novel Rise of Combined Dermatology-Rheumatology Clinics
Rheumatology News has a novel online report about combined rheumatology-dermatology clinics. In the last several years, there have been a few of these in operation (Boston, Chicago, Rhode Island).
Read Article
RheumNow Week in Review – 22 July 2016
From tofacitinib developmental trials in RA and psoriasis and adherence to T2T in early RA to a rheumatology pearl about dapsone and much more, here are the highlights of what you may have missed on RheumNow.com this week.
Read Article
FDA Panel Recommends Brodalumab Approval in Psoriasis
Valeant Pharmaceuticals International's experimental drug to treat psoriasis should be approved as long as certain measures are put in place to mitigate the risk of suicide, an advisory committee to the U.S. Food and Drug Administration concluded on Tuesday.
Read Article
